DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Food and Drug Administration
[Docket No. FDA-2012-N-0012]
Office of the Commissioner of Food and Drugs; Delegation of Authority
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
Notice is hereby given that I have delegated to the Commissioner of Food and Drugs (the Commissioner) certain authority added to the Public Health Service Act by section 801 of Public Law 110-85, the Food and Drug Administration Amendments Act of 2007 (42 U.S.C. 282(j)), pertaining to the expansion of the Clinical Trial Registry and Results Data Bank described therein. Specifically, the Commissioner is delegated the following authority:
• Section 402(j)(5)(C)(ii) of the Public Health Service Act (42 U.S.C. 282(j)(5)(C)(ii)) --To determine that any clinical trial information was not submitted as required under 42 U.S.C. 282(j) or was submitted but is false or misleading in any particular and to notify the responsible party and give such party an opportunity to remedy non-compliance by submitting required revised clinical trial information not later than 30 days after such notification.
This authority may be redelegated. This delegation will be exercised in accordance with the Department of Health and Human Services’ applicable policies, procedures, guidelines, and regulations. 2 oc2012262
I ratify and affirm any actions taken by the Commissioner or her subordinates that involved the exercise of the authority delegated herein prior to the effective date of this delegation. This delegation is effective upon date of signature.
Date: September 5, 2012.
Kathleen Sebelius,
Secretary of Health and Human Services.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
2 Commerce Drive
Cranbury, NJ 08512